Alternate-day versus once-daily administration of amphotericin B in the treatment of cryptococcal meningitis: A randomized controlled trial

Scandinavian Journal of Infectious Diseases

Volumn 39, Issue 10, 2007, Pages 896-901

  Techapornroong, Malee ^a   Suankratay, Chusana ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; FLUCONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANEMIA; ARTICLE; CHILL; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYPTOCOCCAL MENINGITIS; DEMOGRAPHY; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; FEMALE; HOSPITAL PATIENT; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; LABORATORY TEST; MALE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OUTCOMES RESEARCH; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SIDE EFFECT; THAILAND; THROMBOCYTOPENIA; VOMITING;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CRYPTOCOCCUS NEOFORMANS; DEOXYCHOLIC ACID; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HOSPITALIZATION; HUMANS; MALE; MENINGITIS, CRYPTOCOCCAL; THAILAND; TREATMENT OUTCOME;

EID: 34748926420     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540701383147     Document Type: Article

References (20)

1. Chariyalertsak, S., Sirisanthana, T., Saengwonloey, O. and Nelson, KE. (2001) Clinical presentation and risk behaviours of patients with acquired immunodeficiency syndrome in Thailand, 1994-1998: Regional variation and temporal trends. Clin Infect Dis, 32, pp. 955-962.
2. Saag, MS, Graybill, RJ, Larsen, RA, Pappas, PG, Perfect, JR and Powderly, WG (2000) Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis, 30, pp. 710-718.
3. van der Horst, CM, Saag, MS, Cloud, GA, Hamill, RJ, Graybill, JR and Sobel, JD (1997) Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med, 337, pp. 15-21.
4. Pitisuttithum, P., Tansuphasawadikul, S., Simpson, AJ, Howe, PA, White, NJ. A., of, AIDS-associated prospective study and amphotericin, B. cryptococcal meningitis in Thailand treated with high-dose (2001) J Infect, 43, pp. 226-233.
5. Andes, D., Stamsled, T. and Conklin, R. (2001) Pharmacodynamics of amphotericin B in neutropenic mouse disseminated-candidiasis model. Antimicrob Agents Chemother, 45, pp. 922-926.
6. Walsh, TJ, Garrett, K., Feurestein, E., Girton, M., Allende, M. and Bacher, J. (1995) Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography: A novel, non-invasive method for measuring responses to antifungal therapy. Antimicrob Agents Chemother, 39, pp. 1065-1069.
7. Dodds, ES, Drew, RH and Perfect, JR. (2000) Antifungal pharmacodynamics: review of the literature and clinical applications. Pharmacother, 20, pp. 1335-1355.
8. Walsh, TJ, Goodman, JL, Pappas, P., Bekersky, I., Buell, DN and Roden, M. (2001) Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: Maximum tolerated dose study. Antimicrob Agents Chemother, 45, pp. 3487-3496.
9. Chabot, GG, Pazdur, Valeriote, FA and Baker, LH. (1989) Pharmacokinetics and toxicity of continuous infusion amphotericin B in cancer patients. J Pharm Sci, 78, pp. 307-310.
10. Walsh, TJ, Finberg, RW, Arndt, C., Hiemenz, J., Schwartz, C. and Bodensteiner, D. (1999) Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses study Group. N Engl J Med, 340, pp. 764-771.
11. Eriksson, U., Seifert, B. and Schaffner, A. (2001) Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 h: Randomized controlled trial. Br Med J, 322, pp. 579-582.
12. Saag, MS, Powderly, WG, Cloud, GA, Robinson, P., Grieco, MH and Sharkey, PK (1992) Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med, 326, pp. 83-89.
13. Imhof, A., Walter, RB and Schaffner, A. (2003) Continuous infusion of escalated doses of amphotericin B deoxycholate: An open-label observational study. Clin Infect Dis, 36, pp. 943-951.
14. Peleg, AY and Woods, ML. (2004) Continuous and 4 h infusion of amphotericin B: A comparative study involving high-risk haematology patients. J Antimicrob Chemother, 54, pp. 803-808.
15. Hiemenz, JW. (2003) Amphotericin B deoxycholate administered by continuous infusion: Does the dosage make a difference?. Clin Infect Dis, 36, pp. 952-953.
16. Heidemann, HT, Gerkens, JF, Spickard, WA, Jackson, EK and Branch, RA. (1983) Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med, 75, pp. 476-481.
17. Gallis, HA, Drew, RH and Pickard, WW. (1990) Amphotericin B: 30 y of clinical experience. Rev Infect Dis, 12, pp. 308-328.
18. Branch, RA. (1988) Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation. Arch Intern Med, 148, pp. 2389-2394.
19. Mayer, J., Doubek, M., Doubek, J., Horky, D., Scheer, P. and Stepanek, M. (2002) Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures animal experiments and clinical study. J Infect Dis, 186, pp. 379-388.
20. Arning, M., Kliche, KO, Heer-Sonderhoff, AH and Wehmeier, A. (1995) Infusion-related toxicity of 3 different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses, 38, pp. 459-465.